Recent EDIT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:06:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:03:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:54:42 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:58:52 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/28/2024 10:13:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 09:39:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:06:57 PM
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:40:25 PM
- Editas Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 01/31/2024 02:00:00 PM
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:15:00 PM
- Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update • Dow Jones News • 12/13/2023 05:48:00 PM
- Editas Medicine Strikes License Deal With Vertex Pharmaceuticals • Dow Jones News • 12/13/2023 02:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:02:25 PM
- Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 • GlobeNewswire Inc. • 12/13/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:23:53 PM
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar • GlobeNewswire Inc. • 12/11/2023 05:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:10:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 09:30:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 09:31:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2023 08:03:51 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM